10x Genomics, a global leader in single cell and spatial biology, has announced the launch of the next generation of its high-performance Flex assay, introducing automation-compatible, plate-based multiplexing for enhanced scalability and efficiency. The new assay is designed to deliver cost-effective, high-throughput single cell analysis, enabling researchers to conduct expansive studies ranging from functional genomics CRISPR screens to FFPE-based translational research.
With this innovation, scientists can now analyze up to 384 samples and 100 million cells per week using a 96-well plate format that integrates seamlessly with 10x’s automated cell partitioning technology. Built upon 10x’s proven Flex chemistry, the updated assay provides exceptional sensitivity, sequencing efficiency, and data quality, all within a scalable, modular workflow. This approach minimizes reagent waste and operational costs while significantly expanding the scope of experiments that can be performed — from single cell discovery to population-scale analysis.
“As we increase scalability and ease of use, researchers are unlocking more — more samples, more conditions, more insights — at a fraction of the previous cost. And as AI-driven approaches evolve, the need for high-quality biological data is only accelerating,” said Michael Schnall-Levin, Founding Scientist and Chief Technology Officer at 10x Genomics. “This next generation of Flex represents a transformational step forward in enabling large-scale, foundational and translational studies, as well as routine single cell use.”
The new Flex assay has already been adopted by early access users across leading research institutions and pharmaceutical companies. Their experiences highlight the assay’s potential to reshape large-scale biological exploration.
“Single cell technologies have transformed our understanding of human health and disease. However, traditional single cell multi-omics approaches have typically profiled only thousands of cells per experiment, making it difficult to scale or capture the complex dynamics that underpin our immune response to disease,” said Peter Skene, Senior Director, High Resolution Immunology at the Allen Institute. “The new 384-plex Flex assay from 10x Genomics is a game changer — enabling the profiling of millions of cells at a fraction of the cost. By fixing cells for batching and ensuring compatibility with liquid-handling automation, we can now explore functional immune responses with unprecedented depth and precision.”
“The next generation of the Flex assay delivers 10x’s most streamlined and robust single cell profiling to date,” added Stephen Christensen, Senior Principal Scientist, Immunology at Pfizer. “The ability to multiplex entire studies and process them in less time will be a powerful enabler for accelerating drug discovery and development.”
With its enhanced scalability, automation, and cost efficiency, the next-generation Flex assay positions 10x Genomics at the forefront of advancing single cell and spatial biology, empowering researchers to generate deeper insights and accelerate breakthroughs in both discovery and translational science.
Also Read
